
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Alloimmunity and Transplantation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1562024
This article is part of the Research Topic Methods in Alloimmunity and Transplantation: 2025 View all articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Face transplant rejection is primarily monitored through skin biopsies, but mucosal tissue may detect immune rejection events missed by skin biopsies.We retrospectively reviewed 47 paired mucosal and facial skin biopsies and 37 paired facial skin and sentinel flap biopsies from nine face transplant recipients. Rejection was graded using the 2007 Banff classification. Correlation, sensitivity, and specificity metrics were assessed.Mucosa and facial skin rejection grades correlated strongly (r = 0.72, p < 0.0001), with mucosa showing a negative predictive value (NPV) of 0.85 for facial skin rejection. Mucosal biopsies identified rejection in 10 cases missed by facial skin biopsies. Sentinel skin biopsies had high correlation but an NPV of 0.76, missing 24% of rejection cases.Mucosal biopsies tend to capture the full spectrum of rejection, whereas skin biopsies alone may miss important rejection events occurring in the mucosa. Mucosal biopsies should be integrated into routine monitoring alongside skin biopsies, as they not only sensitively function as sentinel tissue but also provide critical insights into rejection activity that may otherwise go undetected. This dual approach could improve overall transplant surveillance. Inconsistencies in rejection patterns between the two tissues highlight the need for a reworked grading system.
Keywords: face transplantation, Vascularized composite allotransplantation (VCA), rejection monitoring, rejection, immunology
Received: 16 Jan 2025; Accepted: 10 Mar 2025.
Copyright: © 2025 Kauke-Navarro MD, Huelsboemer, Klimitz, Diatta, Knoedler, Knoedler, Crisler, Brown, Lian, Repetto, Clark, Murphy, Ko and Pomahac. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Martin Kauke-Navarro MD, Yale-New Haven Hospital, New Haven, United States
Bohdan Pomahac, Yale-New Haven Hospital, New Haven, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.